BD (Becton, Dickinson and Company) has announced a development and global distribution agreement with Check-Points for BD MAX assays that detect carbapenem-resistant organisms (CRO).
As part of the agreement, BD will distribute the Check-Direct CPE Screen for the BD MAX assay (CE IVD) outside of the US, with Check-Points maintaining exclusivity in the Netherlands. Check-Points and BD plan to develop and commercialise a next-generation CRO assay for launch outside the US in 2017.
Since 2007 Avensys have been a key player in the national picture of bio-medical equipment sale, repair, maintenance and training. Now owned by HERMED GmbH (part of the VAMED group), Avensys are part of the global medical infrastructure, able to offer a complete service for asset management including procurement, device maintenance, and training.
University of Warwick
8th - 9th August 2025
Stansted Radisson Blu
23rd September 2025
Brighton Centre, UK
29th - 30th September 2025
EICC, Edinburgh
16th - 18th November 2025
